Michael R. Verneris

Michael R. Verneris publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Michael R. Verneris sits on this spectrum.

Michael R. Verneris D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael R. Verneris sits on this spectrum.

Best Publications

• Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

  S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

  5574
  Citations

• Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

  R Coleman Lindsley;Wael Saber;Brenton G Mar;Robert Redd

  799
  Citations

• Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C natural killer cells with potent function

  Bree Foley;Sarah Cooley;Michael R. Verneris;Michelle Pitt

  707
  Citations

• Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

  Claudio G. Brunstein;Jonathan A. Gutman;Daniel J. Weisdorf;Ann E. Woolfrey

  583
  Citations

• Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

  Elena J. Orlando;Xia Han;Catherine Tribouley;Patricia A. Wood

  543
  Citations

• Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.

  Michael R. Verneris;Michael R. Verneris;Mobin Karami;Mobin Karami;Jeanette Baker;Jeanette Baker;Anishka Jayaswal;Anishka Jayaswal

  477
  Citations

• Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein

  Veronika Bachanova;Sarah Cooley;Todd E. Defor;Michael R. Verneris

  469
  Citations

• Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging

  Matthias Edinger;Yu An Cao;Michael R. Verneris;Michael H. Bachmann

  428
  Citations

• Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen

  Bree Foley;Sarah A Cooley;Michael R Verneris;Julie M Curtsinger

  424
  Citations

• Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

  Claudio G. Brunstein;Jeffrey S. Miller;David H. McKenna;Keli L. Hippen

  415
  Citations

• First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

  Rizwan Romee;Sarah Cooley;Melissa M. Berrien-Elliott;Peter Westervelt

  411
  Citations

• Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

  Michelle K. Gleason;Todd R. Lenvik;Valarie McCullar;Martin Felices

  400
  Citations

• IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

  Daniel A. Vallera;Martin Felices;Ron McElmurry;Valarie McCullar

  372
  Citations

• Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT

  Jeffery S. Miller;Sarah Cooley;Peter Parham;Sherif S. Farag

  353
  Citations

• Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

  Michael R. Verneris;Claudio G. Brunstein;Juliet Barker;Margaret L. MacMillan

  344
  Citations

• Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

  Petter S. Woll;Bartosz Grzywacz;Xinghui Tian;Rebecca K. Marcus

  304
  Citations

• Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

  Jeanette Baker;Michael R. Verneris;Maki Ito;Judith A. Shizuru

  295
  Citations

• Advancing animal models of neoplasia through in vivo bioluminescence imaging.

  M. Edinger;Y.-a. Cao;Y.S. Hornig;D.E. Jenkins

  293
  Citations

• One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

  John E. Wagner;Mary Eapen;Shelly Carter;Yanli Wang

  292
  Citations

• CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

  Michelle K. Gleason;Julie A. Ross;Erica D. Warlick;Troy C. Lund

  277
  Citations